Kesimpta (Ofatumumab)

Ofatumumab is a medicine used to treat multiple sclerosis (MS). It is a shot you give yourself under the skin with a pen, usually once a month. It works by lowering certain immune cells, called B cells, that attack the nerves in MS.

Brand names:Kesimpta
Medication

What people taking Kesimpta (Ofatumumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Kesimpta (Ofatumumab) for MS (Multiple Sclerosis)?

NameHow it went

About Kesimpta (Ofatumumab)

What It's For

Ofatumumab, sold as Kesimpta, is a prescription medicine for adults with relapsing forms of multiple sclerosis (MS). That includes relapsing-remitting MS, where symptoms flare in attacks (relapses) and then partly or fully settle; active secondary progressive MS, where disability is gradually worsening but relapses or new inflammation still occur; and clinically isolated syndrome, a first MS-like episode that may or may not turn into MS. Kesimpta is a disease-modifying therapy. It does not treat the symptoms of an attack as they happen. Its job is to reduce how often new attacks and new areas of nerve damage occur, and to slow the build-up of disability over time. It is one of several high-efficacy options a neurologist may suggest, especially for people who want a treatment they can give themselves at home. It is not approved for children or for primary progressive MS, the form that worsens steadily from the start without relapses. A different, intravenous form of ofatumumab, given at much higher doses, has been used to treat a blood cancer called chronic lymphocytic leukemia (CLL); that product is not interchangeable with Kesimpta.

How It Works

In MS, the immune system mistakenly attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. B cells, a type of white blood cell, are thought to help drive these attacks. Ofatumumab is a monoclonal antibody, a lab-made protein designed to lock onto one specific target. Its target is CD20, a marker on the surface of most B cells. Once it attaches, the body's own defenses destroy those cells. Within about two weeks of starting, B cell counts in the blood fall very low, and monthly doses keep them low. With fewer B cells available, the immune attacks that cause relapses and new brain lesions happen far less often. Exactly why this works so well in MS is not fully understood, and lowering B cells also weakens part of the body's defense against infection, which explains several of the medicine's risks.

Dosage & Administration

Kesimpta comes as a single-use prefilled pen (the Sensoready pen) or prefilled syringe, injected under the skin of the belly, thigh or outer upper arm. The standard schedule is three starting doses, one each at weeks 0, 1 and 2, then one injection once a month beginning at week 4. Everyone receives the same 20 mg dose. The first injection is given with a healthcare professional guiding you, because reactions are most likely after that first dose. After that, most people inject at home. Before starting, you will have blood tests for hepatitis B, liver function and antibody (immunoglobulin) levels, and any needed vaccines are ideally brought up to date. The pens are stored in the refrigerator and taken out 15 to 30 minutes before use so the medicine reaches room temperature. If needed, a pen can be kept at room temperature (not above 86°F) for up to 7 days. If you miss a dose, inject it as soon as you remember rather than waiting for the next scheduled date, then continue monthly from there.

Side Effects

The most common side effects are colds and other upper respiratory infections, headache, and reactions after an injection. A systemic injection reaction usually means fever, headache, muscle aches, chills or tiredness within a day of the shot. These were most frequent after the first injection (about 1 in 7 people) and became much less common with later doses; nearly all were mild to moderate. Redness, swelling, itching or pain at the injection spot is also common. Urinary tract infections and back pain occur somewhat more often than with comparison treatment. Because the medicine lowers B cells, infections can become more likely and occasionally serious. Tell your care team about fever, chills, a cough that won't go away or painful urination, both during treatment and in the months after stopping. A dose is usually delayed until an active infection clears. Serious allergic reactions are rare but have been reported, and they can occur with any injection, not only the first. Swelling of the face, lips, tongue or throat, or trouble breathing, needs emergency care right away (call 911). Milder reactions that are new or worse than with earlier doses should still be reported to your prescriber before the next injection.

Interactions & Warnings

Hepatitis B testing is required before the first dose. Kesimpta cannot be used if you have active hepatitis B, and people who had hepatitis B in the past need monitoring with a liver specialist, because B cell-lowering drugs can reawaken the virus. Fatal cases of this happened with high-dose intravenous ofatumumab for leukemia, although none were seen in the MS trials. Using Kesimpta with other medicines that suppress the immune system, including steroid medicines such as prednisone, can add to infection risk. The same applies when switching from another MS treatment whose effects on the immune system are still wearing off, so your neurologist will plan the timing of a switch. Live vaccines (made from weakened forms of a germ) should be given at least 4 weeks before starting and are not recommended during treatment or until B cells recover after stopping. Other vaccines are best given at least 2 weeks before the first dose; they are allowed during treatment but may produce weaker protection. Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection that has occurred with high-dose ofatumumab for leukemia and with similar drugs. It was not seen in the MS trials. Contact your care team promptly about weakness on one side of the body or clumsiness that keeps getting worse over days, changes in vision, or new confusion, memory problems or personality changes. Liver injury has been reported with Kesimpta and related MS drugs, sometimes weeks to months after a dose. Report new tiredness, loss of appetite, nausea or vomiting, pain in the upper right side of the belly, dark urine, or yellowing of the skin or eyes promptly. Kesimpta may harm a developing baby's immune system. Use effective birth control during treatment and for 6 months after the last dose, and tell your prescriber right away if you become pregnant or are planning a pregnancy. It is not known whether ofatumumab passes into breast milk, so breastfeeding is a decision to make with your care team.

What to Expect

Kesimpta acts quickly on the immune system, with B cells falling within the first couple of weeks, but its benefit shows up over months and years as fewer relapses and fewer new lesions on MRI (magnetic resonance imaging) scans of the brain. In two large trials lasting up to about two and a half years, people taking it had roughly half as many relapses per year as people taking teriflunomide, an oral MS medicine, and far fewer new brain lesions. Somewhat fewer had their disability worsen (about 11% versus 15% over two years). It does not reverse damage that has already happened, and some people still have relapses or gradual progression. Treatment is meant to continue long term. Your neurologist will usually check periodic MRI scans and neurological exams to judge how well it is working, and may repeat blood tests for antibody levels, especially if you get frequent or unusual infections. Low antibody levels were the most common reason people stopped the medicine in the trials. If you stop, B cells typically take around six months to recover, so the effects on infection risk and vaccines linger for a while. Stopping can also allow MS activity to return, so changes are planned with the neurologist rather than made alone.

Questions to Ask Your Doctor

  1. 1.Why is Kesimpta a good fit for my type and activity of MS compared with other treatments, including oral pills or infusions?
  2. 2.Which vaccines should I get before my first dose, and which ones should I avoid while I'm on it?
  3. 3.What blood tests and MRI scans will I need, and how often?
  4. 4.How should I handle a fever or infection around the time an injection is due?
  5. 5.What would planning a pregnancy or switching treatments look like while I'm on Kesimpta?

Last reviewed • Oct 2026

Educational content, not medical advice.